

Original Research Article

Antioxidant and radical scavenging properties of β -carotene on Cisplatin induced cardiotoxicity.

ABSTRACT

ABSTRACT

Objective: To investigate the protective role of β -Carotene against cisplatin induced cardiotoxicity in male albino rats.

Methods: Various biochemical parameters such as Creatine kinase-MB, Lactate dehydrogenase (LDH), Alkaline phosphatase (ALP), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Triglycerides (TG) and Total cholesterol (TC) are being assessed. Also the levels of the *in vivo* antioxidants such as Reduced glutathione (GSH), Catalase(CAT), and Malondialdehyde (MDA) in the post mitochondrial supernatant of heart were measured. In addition, the histopathological studies were performed to study the protective activity of β -carotene.

Results: Cisplatin administration has shown the elevated levels of the cardiac markers and diminished the endogenous antioxidant levels when compared with the normal rats. β -carotene treatment showed the inhibitory effect on the free radicals showing decreased levels of the cardiac markers like CK-MB, LDH, AST, ALT and ALP. The β -carotene treated rats showed significant ($p<0.001$) decrease in lipid peroxidation in both prophylactic and curative groups when compared to the cisplatin group. Also showed a significant ($p<0.05$, $p<0.001$) increase in the levels of GSH in prophylactic and curative group respectively when compared with the cisplatin group. Both prophylactic and curative groups have shown a significant ($p<0.001$) increase in the levels of CAT. Further, the histopathological studies confirm the protective effect of β -carotene.

Conclusion: These findings justify the biological and traditional uses of β -carotene as confirmed by its promising radical scavenging activity against cisplatin induced cardiotoxicity.

Keywords: β -Carotene, Cardiotoxicity, Lipid Peroxidation, Reduced glutathione, Catalase, Post mitochondrial supernatant.

1. INTRODUCTION

Cisplatin(CP) is widely used and highly effective antineoplastic agent. It remains as a standard component for the treatment of head and neck tumours. It is also used to treat many solid tumours, including those of the lung, testis, ovary and breast etc. The main dose limiting side effect is nephrotoxicity which was recognized since its introduction [1].

Besides, it also causes several dose dependent adverse effects, notably neurotoxicity, hepatotoxicity, and cardiotoxicity etc [2][3]. Administration of cisplatin with other antineoplastic drugs like methotrexate, 5-fluorouracil, bleomycin and doxorubicin are associated with lethal cardiomyopathy [4]. The emergence of the cardiotoxicity which includes the changes in the cardiac events such as arrhythmias, cardiomyopathy, electro-cardiographic changes and congestive heart failure is being reported in many case reports. Though intense efforts are made over decades to find the equally potent but less toxic drug, cisplatin is widely prescribed [5][6].

Carotenoids are a group of naturally occurring fat-soluble compounds. Over 700 naturally occurring carotenoids are identified so far. β -carotene (BC) is one of the most prominent natural antioxidants, orange-coloured carbon-hydrogen carotenoid and a precursor of vitamin A [7][8]. It is an organic hydrocarbon containing compound specifically referred as a terpenoid, reflecting its derivation from isoprene units. BC is a common substance abundant in yellow-orange fruits and vegetables (eg: carrots, pumpkins and sweet potatoes etc.) and in dark green leafy vegetables and also the most widely distributed carotenoid in foods that colours them orange [9]. It is known to induce hepatic enzymes that detoxify the carcinogens in a rat model [10], has strong inhibitory effect against DMH (1,2-dimethylhydrazine) induced colon tumours [11]. Moreover, BC has an ability to function as a chain breaking antioxidant in the lipid environment at partial pressures of oxygen that are more likely considered in mammalian cells[12].

The BC molecule reacts with the free radical, resulting in the formation of a new much more stable radical possibly due to the presence of a conjugated double bond system which facilitates a resonance condition [13]. It is known that β -carotene can quench singlet oxygen with a multiple higher efficiency than α -tocopherol. The *in vitro* studies have shown the potent antioxidant activity of BC [7].

Nutrition has a prominent role in the prevention of many chronic disease such as cancers, degenerative brain diseases and cardiovascular diseases. The consumption of food based antioxidants including BC seems to be useful for the prevention of cataracts and macular degeneration. Several studies have revealed the protective effect of food based BC, along with diet rich in fruits and vegetables, on liver carcinogenesis as well the lung disease [7].

Earlier literature suggests the beneficial effects of use of antioxidants such as silymarin, acetyl-L-carnitine & DL- α -lipoic acid which are proven to be potential against the cardiotoxicity associated with cisplatin in experimental animals [4]. Most endogenous compounds exhibit antioxidant functions which often act synergistically with the antioxidants supplied through the dietary origin [14].

The role of BC in the prevention of cardiotoxicity, especially by CP has not been established yet; the focus on the most important non enzymatic antioxidant activity of BC in scavenging the oxygen free radicals released by the administration of cisplatin is being assessed. The protective effect of β -carotene on heart is studied by estimating various biochemical parameters, antioxidant parameters (on the post mitochondrial supernatant of the organ) and the histopathological findings.

51

52 **2 MATERIALS AND METHODS**

53 **2.1 Chemicals & Drugs**

54 Cisplatin injection available as Cytoplatin 50mg/50ml manufactured by cipla is used. β -carotene was
55 obtained from sigma aldrich. The biochemical kits used are obtained from Coral, Excel and Span
56 diagnostics. All the chemicals used were of analytical grade.

57 **2.2 Animals & Experimental design**

58 Male albino Wistar rats were purchased from Teena labs, Hyderabad. The animals are subjected to
59 acclimatization for one week provided with food and water *ad libitum*. The animals were maintained at
60 a controlled temperature under 12hrs dark/light cycle in the animal house at CMR College of
61 pharmacy, Hyderabad approved by CPCSEA (657/PO/a/12/CPCSEA -June, 2012).

62 The experimental animals weighing 200-250g were used in the studies which were divided into five
63 groups containing six in each. The treatment is followed according to the details mentioned in table 1.
64 Blood samples are collected after 2 hrs of the treatment on the last day. The blood was withdrawn by
65 retro-orbital puncture and the animals were sacrificed by spinal dislocation [15]. The changes in body
66 weights are noted. Olive oil is used as vehicle for administration of BC.

2.3 Biochemical estimations

The blood samples obtained are centrifuged at 3000g for 10 mins at 4°C and the serum obtained from the blood was used for the evaluation of biochemical parameters such as CK-MB, LDH, AST, ALT, ALP, TG and TC. Hearts were rapidly excised, trimmed of connective tissue and weighted, subjected to washing with ice-cold normal saline to make free from blood and were used for the preparation of post mitochondrial supernatant for *in vivo* antioxidant studies and histopathological studies.

In vivo antioxidant studies

The tissue homogenates (10% w/v) were prepared with a Teflon homogenizer using ice-cold 1.15% KCl [16]. The homogenates were centrifuged at 800g for 5 min at 4°C (REMI C-24) to separate the molecular debris. The Post mitochondrial supernatant is collected after centrifuging at 10000g for 20 mins which was used for *in vivo* antioxidant parameters like lipid peroxidation (LPO), Catalase (CAT) and reduced glutathione (GSH).

2.3.1 Estimation of Lipid Peroxidation (LPO)

The procedure was followed according to the modified method of [17]. The PMS of volume 0.5ml was allowed to react with 0.5ml tris HCl buffer (pH 7.4) and incubated at 37°C for 2 hrs followed by addition of 1ml of 10% ice cold trichloroacetic acid and centrifuged at 1000rpm for 10 mins and 1ml supernatant was added to 1ml of 0.67% w/v thiobarbituric acid and boiled for 10 mins. After cooling 1ml distilled water is added and the absorbance was measured at 532 nm against the blank without tissue homogenate. The malondialdehyde (MDA) content, a measure of lipid peroxidation was assayed in the form of TBARS.

2.3.2 Estimation of Reduced Glutathione (GSH)

Modified method of [18], the PMS of volume 0.75ml is mixed with equal volume of 4% sulfosalicylic acid and centrifuged at 1200g for 5 mins at 4°C. 0.5ml of supernatant was added with 4.5ml of 0.01M DTNB and the absorbance was measured at 412 nm against the blank without tissue homogenate.

2.3.3 Estimation of Catalase (CAT)

According to the modified method of [19], the tissue homogenate in volume 0.05 ml was diluted with 1.95 ml of 0.05M phosphate buffer (pH 7.0) and for 2ml of the diluted homogenate 1ml of 0.019 M hydrogen peroxide (prepared using 0.05M phosphate buffer) was added and immediately the absorbance was measured at 240nm against the blank without tissue homogenate for 2 minutes with 60 seconds intervals and the average is considered.

2.3.4 Statistical analysis

The statistical analysis was carried out using one way ANOVA followed by tukey's multiple comparison test and the values were expressed as mean $\pm$ SEM. Values at $P < 0.05$ are considered statistically significant.

3. RESULTS

Protective effects of BC against CP induced cardiotoxicity was established by observing the parameters such body weight, heart weight, cardiac biomarkers such as CK MB and endogenous antioxidants.

Body weight and heart weight: The animals treated with CP significantly ($p < 0.001$) decreased the body weight when compared to the normal rats. Also, significant ($p < 0.001$) decrease in the weight of the heart when compared with the normal rats as mentioned in the Table 2.

Biochemical estimation: The animals treated with CP have shown the elevated levels of the enzymatic markers such as CK MB, LDH, AST, ALT and ALP when compared to normal rats. It also has shown the elevated levels of Triglycerides (TG) and Total cholesterol (TC). The treatment groups both

prophylactic and curative has shown significant reduction of the markers in serum as represented in the Table no. 2 & 3.

Antioxidant biomarkers: The elevated levels of MDA clearly indicate the myocardial damage with a significant reduction in the non-enzymatic antioxidants such as GSH and CAT. Upon treatment, both groups (prophylactic and curative) showed a significant decrease in lipid peroxidation levels and would have successfully defended in the depletion of GSH and CAT as the details mentioned in table 4.

Histopathological Observations: The hearts of the animals were dissected out soaked in 10% formalin solution, stained with eosin and haematoxylin. 5 µm thick sections were observed under light microscope with magnification 100x. The histopathological studies according to [6][20], have shown the cardiac damage including, degenerative changes and necrosis of cardiac muscle fibre cells with fibrous tissue reaction in cisplatin group. The hearts of the Prophylactic and curative groups showed decreased myocardial necrosis.

DISCUSSION

Chemotherapy, especially using CP declines the normal homeostasis of the body [21]. Cisplatin is still a frequently used chemotherapeutic agent due to its potential activity on carcinoma cells, despite of its frequent adverse effects. There are various outcomes to attenuate its toxicity which includes dose optimization, excess hydration therapy, use of osmotic diuretics etc though of limited usefulness [22].

During the physiological process the electrons continuously escape from respiratory chain partially reduces the molecular oxygen generating the superoxide anions, precursors of ROS which are continuously produced in mitochondria. The efficient mitochondrial antioxidant defense system maintains the balance between the generation of ROS and detoxification. The administration of cisplatin imbalances the ratio by enhancing the ROS generation and depletion of the endogenous enzymatic antioxidants such as GSH, and CAT [23]. The ROS generated by cisplatin during this process triggers the mitochondrial permeability transition pore opening which permits the release of cytochrome c from mitochondria to cytosol activating the mitochondrial pathway leading to apoptosis. Also, cisplatin is converted to highly reactive form, which reacts with thiol containing compounds such as glutathione and causes its depletion [4].

GSH is low molecular weight endogenous radical scavenger in the cytoplasm and is one of the important inhibitors of free radical generation mediated by lipid peroxidation [20]. The reduction in the GSH and other related endogenous antioxidants by cisplatin, shifts the cellular redox status leading to the accumulation of endogenous ROS within the cells enhancing the lipid peroxidation which is another pathway for the cardiac cells damage [24][25]. The oxidative stress reflects a shift towards the imbalance of the antioxidant defense system leading to the damage of the cellular components, notably proteins, membrane lipids and nucleic acids, leading to the leakage of cardiac markers which indicate the cardiac injury [26][27].

In the present study the administration of single intraperitoneal dose of CP (7mg/kg) [28] has shown the significant elevation of the serum cardiac markers such as CK MB, LDH, AST, ALT and ALP when compared to the normal rats [20]. The ROS generated due to the administration of CP (7mg/kg) might have caused the membrane injury indicated by the lipid peroxidation causing the loss of function and integrity of myocardial membrane leading to the leakage of the cardiac markers into the circulation. The administration of BC protected the myocytes against CP by decreasing their susceptibility to the free radicals.

BC is one the most prominent natural compound with lipophilic nature which contains an extended system of conjugated double bonds which are responsible for their antioxidant activity. The mechanisms by which BC protect biological systems, associated with lowered DNA damage, decreased lipid peroxidation against oxidative damage tends to depend largely on the polyene chain in the center of the molecule which is responsible for physical quenching [29][30]. Singlet oxygen, though it is short lived, can be intercepted by reactions occurring near diffusion control, the process of physical quenching which is the main domain for carotenoids [14]. Carotenoids undergo oxidation, which involves the interruption of conjugated double bond system either by cleavage or by addition to one of the double bonds of BC molecule. The possible mechanisms by which carotenoids scavenge free radicals include either radical addition, electron transfer to the radical or the allylic hydrogen abstraction leads to the formation of stable metabolites [30]. The phenolic antioxidants like Flavanoids, phenolic acids (cinnamic acid and hydroxylated benzoic acid), tocopherols and ascorbic acid exerts their radical scavenging activity by their hydroxyl groups (combined with a conjugated double bond system) at the outer part of the molecule reacting with the radicals to form a resonance-stabilized radical [30][31][32][33].

The biological defense developed can be classified as prevention, interception and repair. The defense against the highly reactive hydroxyl radical can only be by prevention or repair because any agent capable of interception would have to be present at very high concentrations, which would be biologically intolerable simply for osmotic reasons [14]. Generally, the repair occurs via enzymatic mechanisms, which are important for the repair of DNA damage before it is fixed as mutation. Also, the reacylation is the main pathway by which the repair of phospholipids and repair or synthesis of proteins occur [14].

The increase in the levels of LPO and the decrease in the levels of GSH and CAT in the present study clearly indicate the oxidative stress induced by CP. The increased lipid peroxidation leads to the increased utilisation of GSH in the heart, as observed in our study. The prophylactic and curative groups have shown the significant reduction in lipid peroxidation levels which is indicated by the recovered levels of GSH and CAT. The leakage of the markers such as CK MB, LDH, AST, ALT and ALP from the cardiac myocytes significantly reduced possibly due to the protective effect of BC against free radicals when compared to CP group.

In conclusion, the results of the study suggest that the suppression of the oxidative stress by BC could be an effective strategy for the treatment of CP induced cardiomyopathy. However further studies have to be performed to confirm the therapeutic activity of BC in the patients receiving CP chemotherapy.

REFERENCES

- [1] Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of Cisplatin Nephrotoxicity. *Toxins* 2010;**2**(11):2490-518.
- [2] Al-Majed AA. Carnitine Deficiency Provokes Cisplatin-Induced Hepatotoxicity in Rats . *Basic & Clinical Pharmacology & Toxicology* 2006;**100**:145-150.
- [3] Hussein A, Ahmed AA, Shouman SA, Sharawy S. Ameliorating effect of DL- α -lipoic acid against cisplatin-induced nephrotoxicity and cardiotoxicity in experimental animals. *Drug Discov Ther* 2012;**6**(3):147-56.
- [4] El-Awady el-SE, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. *Eur J Pharmacol* 2011;**650**(1):335-41.

- 202 [5] El-sayed EM, EL-azeem ASA, Afify AA, Shabana MH, Ahmed HH. cardioprotective effects
203 *Curcuma longa* L. extracts against doxorubicin-induced cardiotoxicity in rats. *J Med Plants Res*
204 2011;**5**(17):4049-58.
- 205 [6] Attyah AM, Ismail SH. Protective Effect of Ginger Extract against Cisplatin-Induced
206 Hepatotoxicity and Cardiotoxicity in Rats. *Iraqi J Pharm Sci* 2012;**21**(1): 27-33.
- 207 [7] Mueller L, Boehm V. Antioxidant activity of β -carotene compounds in different *in vitro* assays.
208 *Molecules* 2011;**16**:1055-69.
- 209 [8] Morakinyo AO, Iranloye BO, Oyelowo OT, Nnaji J. Anti-oxidative and hepatoprotective effect of
210 beta-carotene on acetaminophen-induced liver damage in rats. *Biol & Med* 2012;**4**(3):134-40.
- 211 [9] Van Arnum SD. Vitamin A. *Kirk-Othmer Encyc Chem Tech* 2000;**45**:99–107.
- 212 [10] Patrick L. Beta-carotene: The controversy continues. *Alt med Rev* 2000;**5**(6):530-45.
- 213 [11] Temple NJ, Basu TK. Protective effect of β -carotene against colon tumors in mice. *JNCI*
214 1987;**78**(6):1211-4.
- 215 [12] Azeim BHA, Abd-Ellah HF, Mohamed NE. Prophylactic role of β -carotene against acrylonitrile-
216 induced esticular toxicity in rats: Physiological and microscoical studies. *J Bas & App Zoolo*
217 2012;**65**:257-66.
- 218 [13] Bendich A. From 1989 to 2001: What Have We Learned About the “Biological Actions of Beta-
219 Carotene”? *J Nutr* 2004;**134**(1):225S-30S.
- 220 [14] Sies H, Stahl W. Vitamins E and C, β -carotene, and other carotenoids as antioxidants. *Am J Clin*
221 *Nutr* 1995;**62**:1315S-21S.
- 222 [15] Khanam S, Mohan NP, Devi K, Sultana R. Protectiv role of *Tinospora cordifolia* against cisplatin
223 induced nephrotoxicity. *Int J Pharm & Pharm Sci* 2011;**3**(4):268-70.
- 224 [16] Katalinic V, Modun D, Music I, Boban M. Gender differences in antioxidant capacity of rat tissues
225 determined by 2,2V-azinobis (3-ethylbenzothiazoline 6-sulfonate; ABTS) and ferric reducing
226 antioxidant power (FRAP) assays. *Comp Biochem & Physiol* 2005;**140**:47-52.
- 227 [17] Niehaus WG, Samuelsson B. Formation of malondialdehyde from phospholipids arachidonate
228 during microsomal lipid peroxidation. *Eur J Biochem* 1968;**6**:126-30.
- 229 [18] Jollow D, Mitchell L, Zampaglione N, Gillete J. Bromobenzene induced liver necrosis: protective
230 role of glutathione and evidence for 3, 4-bromobenzenoxide as the hepatotoxic intermediate.
231 *Pharmacol* 1974;**11**:151-169.
- 232 [19] Hugo EB. (1984). Oxidoreductases acting on groups other than CHOH: Catalase. In: Colowick
233 SP, Kalpan NO, Packer, L. (editors). *Methods in enzymology*. London: Academic Press: 121-25.
- 234 [20] Viswanatha Swamy AH, Patel UM, Koti BC, Gadad PC, Patel NL, Thippeswamy AH.
235 Cardioprotective effect of *Saraca indica* against cyclophosphamide induced cardiotoxicity in rats:
236 a biochemical, electrocardiographic and histopathological study. *Ind J Pharmacol* 2013;**45**(1):44-
237 8.
- 238 [21] Yousef MI, Saad AA, El-Shennawy LK. (2009). Protective effect of grape seed proanthocyanidin
239 extract against oxidative stress induced by cisplatin in rats. *Food Chem. Toxicol* 2009;**47**:1176–
240 83.

- 241 [22] Domitrović R, Potočnjak I, Crnčević-Orlić Z, Škoda M. Nephroprotective activities of rosmarinic
242 acid against cisplatin-induced kidney injury in mice. *Food Chem Toxicol* 2014;**66**:321-8.
- 243 [23] Hadi AA, Thamir SNA. Evaluation of the Protective Properties of Amlodipine, on Cisplatin
244 Induced Cardiotoxicity in Male Rats. *Glo J Med Res Interd* 2013;**13**(2):23-8.
- 245 [24] Arany I, Safirstein RL. Cisplatin nephrotoxicity. *Semin. Nephrol* 2003;**23**:460–64.
- 246 [25] Karthikeyan K, Bai BR, Devaraj SN. Cardioprotective effect of grape seed proanthocyanidins on
247 isoproterenol-induced myocardial injury in rats. *Int. J. Cardiol* 2007;**115**:326–33.
- 248 [26] Conklin KA, Nicolson GL. Molecular replacement in cancer therapy: reversing cancer metabolic
249 and mitochondrial dysfunction, fatigue and the adverse effects of cancer therapy. *Curr Cancer*
250 *Ther Rev* 2008;**4**:66–76.
- 251 [27] Satoh M, Kashihara N, Fujimoto S, Horike H, Tokura T, Namikoshi T, et al. A novel free radical
252 scavenger, edarabone, protects against cisplatin-induced acute renal damage in vitro and in vivo.
253 *J Pharmacol Exp Ther* 2003;**305**:1183–90.
- 254 [28] El-Sawalhi MM, Ahmed LA. Exploring the protective role of apocynin, a specific NADPH oxidase
255 inhibitor, in cisplatin-induced cardiotoxicity in rats. *Chem Biol Interact* 2014;**207**:58-66.
- 256 [29] Mayne ST. Beta-carotene, carotenoids, and disease prevention in humans. *The FASEB Journal*
257 1996;**10**:690-701.
- 258 [30] Müller L, Fröhlich K, Böhm V. Comparative antioxidant activities of carotenoids measured by
259 ferric reducing antioxidant power (FRAP), ABTS bleaching assay (α TEAC), DPPH assay and
260 peroxy radical scavenging assay. *Food Chemistry* 2011;**129**:139-48.
- 261 [31] Miller NJ, Sampson J, Candeias LP, Bramley PM, Rice-Evans CA. Antioxidant activities of
262 carotenoids and xanthophylls. *FEBS Letters* 1996;**384**:240-42.
- 263 [32] Kamal-Eldin A, Appelqvist LA. The chemistry and antioxidant properties of tocopherols and
264 tocotrienols. *Lipids* 1996;**31**:671-701.
- 265 [33] El-Agamey A, Lowe GM, McGarvey DJ, Mortensen A, Phillip DM, Truscott TG, et al. Carotenoid
266 radical chemistry and antioxidant/pro-oxidant properties. *Arch. Biochem Biophys* 2004;**430**:37-
267 48.

268

269

270

271

272

273

274

TABLES

Table 1: Treatment schedule

Group	Drug Treatment	Dose	Duration in days	Day of withdrawal of blood/ sacrifice	Purpose
I	Vehicle	1ml/kg	1-7	7 th	Normal control
II	Cisplatin	7 mg/kg	1 st	5 th	Disease control
III	β-carotene	10 mg/kg	1-7	7 th	BC control
IV	β-carotene Cisplatin	10 mg/kg 7 mg/kg	1-7 3 rd	7 th	Prophylactic
V	Cisplatin β-carotene	7 mg/kg 10mg/kg	1 st 5-11	11 th	Curative

Table 2: Effect of BC on CP induced changes in body weights, heart weights and various biochemical markers

Group	Treatment	Changes in Body weight (gms)	Heart Weight (mg)	CK MB (U/L)	LDH (U/L)
I	Normal	12.3 ± 1.59	739.2 ± 17.19	667.4 ± 29.03	408.9 ± 17.47
II	CP	-23.67 ± 2.51 ^x	559.3 ± 19.23 ^x	2560.0 ± 110.00 ^x	1760.0 ± 57.19 ^x
III	BC	19.33 ± 2.06 ^a	774.3 ± 10.82 ^a	635.4 ± 53.26 ^a	368.7 ± 12.66 ^a
IV	BC + CP	-2.00 ± 2.78 ^a	658.2 ± 9.20 ^a	705.9 ± 59.18 ^a	586.7 ± 36.16 ^a
V	CP + BC	-13.8 ± 1.22 ^c	604.3 ± 19.00 ^a	1147.0 ± 71.07 ^a	724 ± 44.64 ^a

Values are expressed as (Mean ± SEM). ^x p<0.001, ^y p<0.01 when compared to normal group

^a p<0.001, ^b p<0.01, ^c p<0.05 when compared to cisplatin control group

Table 3: Effect of BC on CP induced changes in various biochemical markers and antioxidant biomarkers.

Group	Treatment	TG (mg/dl)	TC (mg/dl)	ALP (U/L)	AST (U/L)	ALT (U/L)
I	Normal	48.7 ± 3.75	49.6 ± 3.45	308.2 ± 8.45	151.4 ± 12.67	26.7 ± 1.17
II	CP	68.7 ± 3.05 ^y	71.1 ± 3.26 ^x	650.4 ± 12.72 ^x	271.9 ± 15.98 ^x	78.5 ± 5.01 ^x
III	BC	46.3 ± 3.00 ^a	42.3 ± 3.54 ^a	292.5 ± 15.90 ^a	149.1 ± 7.70 ^a	24.4 ± 1.90 ^a
IV	BC + CP	54.6 ± 3.53 ^c	51.3 ± 1.63 ^a	329.0 ± 17.89 ^a	163.8 ± 4.14 ^a	29.3 ± 2.28 ^a
V	CP + BC	56.5 ± 2.36 ^{ns}	58.6 ± 3.14 ^c	441.0 ± 14.07 ^a	199.6 ± 5.04 ^a	33.1 ± 1.10 ^a

Values are expressed as (Mean ± SEM). ^xp<0.001, ^yp<0.05 compared to normal group.

^ap<0.001, ^bp<0.01, ^cp<0.05 when compared to cisplatin control group

Table 4: Effect of BC on CP induced changes in various antioxidant biomarkers.

Group	Treatment	MDA (nmol/g)	GSH (nmol/g)	CAT (nmol/g)
I	Normal	1.1 ± 0.05	4.2 ± 0.36	16.7 ± 0.64
II	CP	9.7 ± 0.41 ^x	1.6 ± 0.20 ^x	3.4 ± 0.23 ^x
III	BC	1.4 ± 0.36 ^a	4.3 ± 0.36 ^a	17.3 ± 1.52 ^a
IV	BC + CP	2.2 ± 0.58 ^a	3.9 ± 0.45 ^a	16.0 ± 1.40 ^a
V	CP + BC	3.5 ± 0.49 ^a	3.7 ± 0.23 ^b	18.0 ± 1.97 ^a

Values are expressed as (Mean ± SEM). ^xp<0.001 compared to normal group ^ap<0.001, ^bp<0.01, ^cp<0.05 when compared to cisplatin control group

FIGURES

Figure 1: Effect of BC on Cisplatin induced changes in various changes in biochemical parameters such as CK-MB, LDH and ALP






Figure 2: Effect of β -carotene on Cisplatin induced changes in various changes in biochemical parameters such as TC and TG




340 Figure 3: Effect of BC on Cisplatin induced changes in various changes in biochemical parameters
341 such as AST and ALT



342

343

344 Figure 4: Effect of BC on Cisplatin induced changes in various changes in antioxidant parameters
345 such as GSH, CAT and LPO.




346

347

348

349 Figure 5: Photomicrographs of histological changes of cardiac tissue under light microscopy with
350 magnification 100X.



351 The Cardiac damage produced by cisplatin showing the degenerative changes and necrosis of
352 cardiac muscle fibre cells. Prophylactic(d) and curative(e) groups showing decreased myocardial
353 necrosis.

354